Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert K Stuart

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Current Treatment Options in Oncology|December 31, 2003
Salivary gland neoplasmsTerry A Day, John Deveikis, M Boyd Gillespie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 30, 2018
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid LeukemiaTodd A Fehniger, Jeffrey S Miller, Robert K Stuart, et al.
Cancer Chemotherapy and Pharmacology|May 18, 2019
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemiasTara L Lin, Laura F Newell, Robert K Stuart, et al.
Leukemia Research|September 22, 2019
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemiaDaniel J DeAngelo, Alison R Walker, Richard F Schlenk, et al.
Leukemia & Lymphoma|November 26, 2019
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemiaJonathan E Kolitz, Stephen A Strickland, Jorge E Cortes, et al.
British Journal of Haematology|November 30, 2010
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemiaAnjali S Advani, Holly M Gundacker, Olga Sala-Torra, et al.
Haematologica|November 9, 2014
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemiaJeffrey E Lancet, Gail J Roboz, Larry D Cripe, et al.
Blood|April 18, 2013
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H Petersdorf, Kenneth J Kopecky, Marilyn Slovak, et al.
Current Treatment Options in Oncology|January 15, 2003
Oral cancer treatmentTerry A Day, Betsy K Davis, M Boyd Gillespie, et al.
British Journal of Haematology|November 19, 2014
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemiaRobert K Stuart, Larry D Cripe, Michael B Maris, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Current Treatment Options in Oncology|December 31, 2003
Salivary gland neoplasmsTerry A Day, John Deveikis, M Boyd Gillespie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 30, 2018
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid LeukemiaTodd A Fehniger, Jeffrey S Miller, Robert K Stuart, et al.
Cancer Chemotherapy and Pharmacology|May 18, 2019
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemiasTara L Lin, Laura F Newell, Robert K Stuart, et al.
Leukemia Research|September 22, 2019
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemiaDaniel J DeAngelo, Alison R Walker, Richard F Schlenk, et al.
Leukemia & Lymphoma|November 26, 2019
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemiaJonathan E Kolitz, Stephen A Strickland, Jorge E Cortes, et al.
British Journal of Haematology|November 30, 2010
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemiaAnjali S Advani, Holly M Gundacker, Olga Sala-Torra, et al.
Haematologica|November 9, 2014
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemiaJeffrey E Lancet, Gail J Roboz, Larry D Cripe, et al.
Blood|April 18, 2013
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H Petersdorf, Kenneth J Kopecky, Marilyn Slovak, et al.
Current Treatment Options in Oncology|January 15, 2003
Oral cancer treatmentTerry A Day, Betsy K Davis, M Boyd Gillespie, et al.
British Journal of Haematology|November 19, 2014
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemiaRobert K Stuart, Larry D Cripe, Michael B Maris, et al.
Pageof 5